Myriad 'applauds' USPSTF recommendation on BRCA-related cancer prevention
Myriad Genetics announced its support of the U.S. Preventive Services Task Force recommendation on expanded hereditary cancer risk assessment for BRCA-related cancers in women. The USPSTF previously recommended that doctors provide hereditary cancer risk assessment for women with a family history of breast or BRCA-related cancers. The task force has expanded that advice and now recommends that primary care doctors assess a woman's risk if they previously were treated for breast or other BRCA-related cancers and are now considered cancer free or have an ancestry that is prone to BRCA mutations. "We applaud USPSTF for recommending hereditary cancer risk assessment for all women with a family or personal history of certain types of cancers or who have an ancestry associated with BRCA mutations," said Royce Adkins, M.D., FACOG, board certified obstetrician-gynecologist and SVP of Medical Affairs, Myriad Women's Health. "There are more than 3.5 million breast cancer survivors who see their OB/GYN or primary care doctors annually. The valuable information provided by hereditary cancer risk assessment can help clinicians select appropriate precision treatments, customize treatment plans and achieve better health outcomes for their patients."